A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder

Vlasios Brakoulias, Emily Stockings

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Introduction: Obsessive-compulsive disorder (OCD) is often viewed as a difficult to treat disorder. In some patients, antipsychotics are used to augment the action of serotonin reuptake inhibitors (SRIs), particularly when there is only a partial response to treatment. Areas covered: This comprehensive literature review aims to assess the effectiveness and tolerability of three commonly used atypical antipsychotic agents: risperidone, paliperidone and aripiprazole, as augmentation agents in the treatment of OCD. Expert opinion: Antipsychotic augmentation should only be trialed once treatment with selective SRIs at high dose and exposure and response prevention therapy have failed. Currently, there is evidence to support the use of risperidone, paliperidone and aripiprazole as augmentation agents for OCD in adult samples but more studies with larger samples are needed to assess predictors of response to antipsychotic augmentation and to detect any differential effects between the three agents. At this point in time, the choice of antipsychotic is best determined by the side effect profile of the drug and a patient’s medication history.
Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number1
DOIs
Publication statusPublished - 2019

Keywords

  • antipsychotic drugs
  • chemotherapy
  • mental health
  • obsessive, compulsive disorder

Fingerprint

Dive into the research topics of 'A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this